Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 218,042,784
  • Shares Outstanding, K 5,960,710
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 1.01
  • Price/Sales 4.09
  • Price/Cash Flow 10.71
  • Price/Book 3.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.15 +4.58%
on 12/07/17
36.82 -0.16%
on 12/12/17
+1.46 (+4.14%)
since 11/13/17
3-Month
34.10 +7.78%
on 10/31/17
36.82 -0.16%
on 12/12/17
+1.70 (+4.85%)
since 09/13/17
52-Week
30.90 +18.96%
on 01/24/17
36.82 -0.16%
on 12/12/17
+3.93 (+11.97%)
since 12/13/16

Most Recent Stories

More News
Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

Regulatory News:

PFE : 36.71 (+0.36%)
CLLS : 27.81 (+15.78%)
U.S. Food And Drug Administration Extends Action Date For XELJANZ(R) (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the supplemental New Drug Application (sNDA) for...

PFE : 36.71 (+0.36%)
Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

CORT : 17.19 (+0.17%)
ONCE : 45.99 (+2.75%)
BMRN : 88.35 (+1.11%)
PFE : 36.71 (+0.36%)
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

AZN : 33.44 (+0.06%)
CLVS : 63.42 (+1.42%)
PFE : 36.71 (+0.36%)
BMY : 63.40 (+0.19%)
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018

Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.

JNJ : 142.61 (+0.01%)
MRK : 56.87 (-0.35%)
VRTX : 143.89 (+2.11%)
BMRN : 88.35 (+1.11%)
INCY : 98.83 (+3.60%)
PFE : 36.71 (+0.36%)
ALXN : 113.54 (-0.05%)
Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

Data include eleventh participant in the trial

ONCE : 45.99 (+2.75%)
PFE : 36.71 (+0.36%)
Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 EMBRACA trial in patients with germline (inherited) BRCA1/2-positive (gBRCA+) locally advanced and/or metastatic breast cancer (MBC)...

PFE : 36.71 (+0.36%)
Pfizer Reports Updated Data from Phase III Study on Ibrance

Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.

AZN : 33.44 (+0.06%)
LLY : 88.15 (+1.66%)
NVS : 84.74 (+0.33%)
PFE : 36.71 (+0.36%)
Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents

Pfizer Inc. (NYSE:PFE) ("Pfizer") today announced that it has commenced a private offer to exchange (the "Exchange Offer") any and all of its outstanding £1,500,000,000 6.500 per cent. Notes...

PFE : 36.71 (+0.36%)
Gene therapy shows promise against blood-clotting disease

Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood...

PFE : 36.71 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 37.12
1st Resistance Point 36.85
Last Price 36.69
1st Support Level 36.28
2nd Support Level 35.98

See More

52-Week High 36.82
Last Price 36.69
Fibonacci 61.8% 34.56
Fibonacci 50% 33.86
Fibonacci 38.2% 33.16
52-Week Low 30.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.